Wykoff, Charles C <br/><br/>
Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).  [electronic resource] 

 -  The British journal of ophthalmology  Jul 2014 
 - 951-5 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1468-2079 
<br/><br/><label>Standard No.: </label>10.1136/bjophthalmol-2013-304736  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--adverse effects<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Exudates and Transudates<br/>Female<br/>Humans<br/>Intravitreal Injections<br/>Male<br/>Middle Aged<br/>Prospective Studies<br/>Ranibizumab<br/>Receptors, Vascular Endothelial Growth Factor--adverse effects<br/>Recombinant Fusion Proteins--adverse effects<br/>Single-Blind Method<br/>Subretinal Fluid<br/>Tomography, Optical Coherence<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Visual Acuity--drug effects<br/>Wet Macular Degeneration--diagnosis